Biotech News
Related news
MNKDMannKind2026-05-27 20:00 EST
MannKind to Present at Jefferies Global Healthcare Conference
MISTMilestone Pharmaceuticals Inc.2026-05-14 12:30 EST
Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
LXRXLexicon Pharmaceuticals2026-05-12 12:30 EST
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
SGMTSagimet Biosciences2026-06-23 00:49 EST
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ALGSAligos Therapeutics2026-09-02 12:00 EST
Aligos Therapeutics to Present at the Cantor Global Healthcare Conference
CVRXCVRx2026-07-28 12:30 EST
CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference
VANIVivani Medical2026-07-14 20:03 EST
Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026
NAMSNewAmsterdam Pharma2026-07-01 12:00 EST
NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026
LXRXLexicon Pharmaceuticals2026-05-28 12:30 EST
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
CVRXCVRx2026-05-27 20:30 EST
CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
MannKind
Inhaled Drug Delivery MannKind develops and commercializes drug-device combinations using Technosphere particles and dry-powder inhalers for rapid, deep-lung delivery. Commercial Portfolio Afrezza is an inhaled mealtime insulin, Tyvaso DPI is manufactured for United Therapeutics, and FUROSCIX provides subcutaneous furosemide for fluid...
Recent company news
MNKDMannKind2026-09-09 10:30 EST
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
MNKDMannKind2026-09-02 12:30 EST
MannKind to Present at Upcoming Investor Conferences
MNKDMannKind2026-08-05 20:01 EST
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
MNKDMannKind2026-07-29 10:30 EST
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
MNKDMannKind2026-07-28 20:01 EST
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
Stock data
- Close
- 3.58 USD
- Market cap
- 1.06B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States